Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature

  title={Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature},
  author={Anand Kumar Annamalai and Andrew F Dean and Narayanan Kandasamy and K{\'a}lm{\'a}n Kov{\'a}cs and Hannah M.M. Burton and David John Halsall and Andrey S Shaw and Nagui M. Antoun and Heok Keong Cheow and Ramez Wadie Kirollos and John D. Pickard and Helen L. Simpson and Sarah J. Jefferies and Neil G. Burnet and Mark Gurnell},
Pituitary carcinoma occurs in ~0.2% of resected pituitary tumours and carries a poor prognosis (mean survival <4 years), with standard chemotherapy regimens showing limited efficacy. Recent evidence suggests that temozolomide (TMZ), an orally-active alkylating agent used principally in the management of glioblastoma, may also be effective in controlling aggressive/invasive pituitary adenomas/carcinomas. A low level of expression of the DNA-repair enzyme O6-methylguanine-DNA methyltransferase… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 23 extracted citations

The role of temozolomide in the treatment of aggressive pituitary tumors.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia • 2015
View 4 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 73 references

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

The Journal of clinical endocrinology and metabolism • 2010
View 20 Excerpts
Highly Influenced

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2007
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…